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Abstract
Off label medicine refers to any medicine that is used to treat any ailment beyond of its approved / licensed 
indication by National Regulatory Authorities, such us FDA in USA and BPOM in Indonesia. Off-label medicines 
are used because the available and approved drugs do not have the desired effect, then doctors try medicine 
that have not been licensed indications. Some other reasons in practice off-label medicines use and prescribing 
are that drugs in the same category have the same effect (although have not been approved by indication), 
the expansion to a lighter form than the licensed indication, or extension of use for certain related conditions. 
At the opposite, the disadvantage of the practice off-label medicine use is generally not included in any health 
insurance benefit package, also not covered by mandatory insurance scheme (JKN-BPJS). Patients should 
pay for the price of a drug that has not been assured or proven of its efficacy and safety. It needs strong 
evidence based on scientific research to ensure the safety and effectiveness of off-label medicines to be 
included in the list of medications (national formulary) to put it on National Health Insurance (BPJS) benefit 
package. 
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Abstrak
Obat off-label adalah obat yang digunakan di luar indikasi yang disetujui oleh lembaga yang berwenang, 
kalau di Amerika Food and Drug Administration (FDA), sedangkan di Indonesia Badan POM.  Obat off label 
digunakan karena obat yang tersedia dan approved tidak memberikan efek yang diinginkan, sehingga dokter 
mencoba obat yang belum disetujui indikasinya. Beberapa alasan lain adalah adanya dugaan bahwa obat dari 
golongan yang sama memiliki efek yang sama (walaupun belum disetujui indikasinya), adanya perluasan ke 
bentuk yang lebih ringan dari indikasi yang disetujui, atau perluasan pemakaian untuk kondisi tertentu yang 
masih terkait. Kerugiannya adalah obat off-label umumnya tidak dicover oleh BPJS sehingga pasien harus 
membayar sendiri harga obat yang belum terjamin efikasi dan keamanannya. Perlu dukungan penelitian yang 
kuat terhadap keamanan dan efektivitas obat off label agar dapat dimasukkan dalam daftar obat (formularium 
nasional) yang ditanggung BPJS.
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Understanding off-label medicine
 Off-label medicine refers to any medicine 
that is used to treat any ailment beyond of its 
approved/licensed indication. Practice of the off-
label prescribing not only based on beyond licensed 
indication, but also apply to the use of a marketed 
medicine in different patient population (e.g. 
paediatric, geriatric, pregnant patient, etc.), dosage, 
or dosage form that does not have approval from the 
authoritative body.1 
 In a drug regulatory system, an authoritative 
body whose responsible for the drug approval in a 
country should approve it licensed indication based 
on the pre-clinical and clinical evidence that is 
provided and submitted by the drug manufacturer. 
This process is to confirm that the given licensed 
drug performs its safety and efficacy in the utmost 
scientific manner. 
 Approval of medicine by the National 
Regulatory Authorities can take years; this process is 
laborious and very-costly. A literature stated that the 
FDA approves not more than 60 percent of all drugs 
submitted for review and a period 6-8 years for a 
Figure  1 Drug Development Process (courtesy of http://www.ppdi.com/About/
About-Drug-Discovery-and-Development)
drug approval.2 Process for drug approval is started 
after a drug is tested for preclinical and clinical trial 
phase III, while the time period for doing pre-clinical 
until successfully end the phase III trial might take 
over more than 10 years. The figure below, show the 
process from drug discovery until approval to the 
medicine regulatory authorities. 
Acceptability and commonality of off-label 
medicine use in standard care
 Paediatric patients is prone to receive off-
label prescribing, as it has been reported in some 
countries, either prospectively or retrospectively 
that the extent of off-label prescribing in paediatrics 
range from 7 to 60%.3 A study in a major paediatric 
teaching hospital in Australia year 2008, off-label 
prescribing occurred in infants and children (31.7% 
and 35.9% respectively); common reasons for off-
label prescribing were dosage (47.4%) and age 
(43.2%).3   
 The high prevalence of off-label use and 
prescribingz shown that this practice is extremely 
common worldwide. 
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 Despite the fact that this practice is done 
without adequate clinical evidence. 
Although on-label medicine is supported by the 
best evidence on its safety and efficacy, but in the 
real population setting the use and prescribing 
not represent the inclusion criteria for its study. 
Limitation in clinical trial setting is not involving 
vulnerable population such as paediatric, pregnant 
woman and elderly, orphan or rare diseases, even 
psychotic. 
 Commonalities in off-label prescribing is 
broad, somehow physician are challenge to prescribe 
CATEGORY and DRUG Example off-label uses(s)
Allergy
• Diphenhydramine Chemotherapy-related emesis, insomnia
Anaesthesiology
• Propofol Intracranial hypertension
• Dexamethasone, propofol Postoperative nausea
Cardiology
• Amiodarone Supraventricular tachycardia
• Indomethacine Pharmacologic closure of patent ductus arteriosus
Dermatology
• Azathioprine Atopic dermatitis, psoriasis
Gastroenterology
• Erythromycin Gastroparesis
• Omeprazole Reflux-related laryngitis
Haematology/oncology
• Alendronate Hypercalcemia of malignancy
• Furosemid (nebulized) Dyspnoea
• Rituximab Idiopathic thrombocytopenic purpura
Infectious diseases
• Linezolid Infective endocarditis
• Sulfamethoxazole-trimetoprim Sinusitis
Nephrology
• Acetylcysteine Prevention of contrast nephrotoxicity
• Erythropoietin Anaemia of chronic diseases
Neurology
• Atenolol Migraine prophylaxis
• Isoflurane Status epilepticus
• Lidocaine Postherapeutic neuralgia
• Tricyclic antidepressants Bulimia, insomnia, neuropathic pain syndrome
Obstetric
• Magnesium sulphate Premature labour
Paediatric
• Morphine Pain in children
• Sildenafil Pulmonary hypertension in children
Pulmonary
• Enflurane, isoflurane, halothane Status asmathicus
Psychiatry
• Beta blockers Social phobia, public speaking
• Fluoxetine Borderline personality disorder, diabetic neuropathy, fibromy-
algia, etc.
• Trazodone Insomnia in elderly patients
Urology
• Sildenafil Sexual dysfunction in women
Table 1 Some examples of the off-label uses of medicine (table is adopted from Wittich, et al1)
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off-label drug since the most available medicine 
to treat an indication is limited. A broad spectrum 
of off-label use of medicine is shown in this table 
below.
 Sildenafil prescribing in Indonesia, the 
manufacturer is on process to license the new dosage 
form that is indicated for pulmonary hypertension 
In case of aspirin, this drug is approved for many 
ailments: pain, fever (the oldest indication), 
rheumatic diseases, wide range of cardiovascular 
diseases.1 patients with history of revascularization 
procedure. Even aspirin is includes in a guideline-
recommended practice as a prophylactic therapy for 
diabetic patients against cardiovascular diseases.1
 In Thailand, the off-label use of 
bevacizumab for age-related macular degeneration 
and diabetic macular oedema is indicated in the 
National List of Essential Medicine (NLEM).4 While 
in Indonesia, the prescribing of sildenafil to treat 
pulmonary hypertension is accepted and subsidized 
by government hospitals, i.e. Sardjito Hospital in 
Yogyakarta and Harapan Kita Hospital in Jakarta. 
Recent updates regarding the use of off-label. 
Concerning legal and ethics in off-label medicine 
prescribing
 Concerning legal aspect in off-label 
medicine use and prescribing, one short answer 
is that “it is not illegal.” In New Zealand, there is 
common law require that off-label drug use is of 
an acceptable standard, that the patient be fully 
informed, and the patient gives informed consent.5 
An article explains that a legal theories used in a 
lawsuit in related to off-label use of medicine is due 
to failure to provide adequate informed consent for 
using and prescribing off-label medicine to patient, 
and medical negligence.1 
 A qualitative study done in Belgium, 
reveals that according to the respondents giving 
information about the working mechanism and risk 
associated with off-label treatment before starting 
it is important.6 The information given to patients 
should be clear and comprehensive.6 It means that by 
providing informed consent on the use of off-label 
medicine, patients held responsible in the shared 
decision making for their own treatment. In the 
future it saves physicians towards any legal lawsuit 
from the patients if the treatment seems to be failing.
 Leaving a patient without adequate treatment 
is considerably unethical to physician’s perspective, 
especially when an evidence is exist although beyond 
the formal authorization process.7 
Concerning the reimbursement systems
 In well developed country, e.g. Germany 
with two-tier health insurance systems, patients 
from private health insurance can use and get off-
label prescription included in the insurance. In the 
opposite, for German citizen who is covered by 
public health insurance there is a strict regulation 
regarding off-label use and prescribing medicine 
that included in the reimbursement public health 
insurance systems.  It  must be proven for efficacy 
if it is used in an off-label manner. The restrictions 
are it is used for treatment of serious diseases, life 
threatening or seriously affects patient’s health 
related quality of life, no other possible therapy and 
must be a reasonable expectation (benefit outweight 
it risk).7
 Thailand has success story to include off-
label medicine in the NLEM, i.e. (1) the use of 
intravenous immunoglobulin for the treatment of 
myasthenia gravis, and (2) bevacizumab for age-
related macular degeneration and diabetic macular 
oedema. This policy is supported by strong evidence 
that the safety, efficacy/effectiveneso, and/or 
efficiency for the use of off-label medicine. 4 Putting 
off-label medicine in a NLEM or National Formlary 
is the first gate toget it covered in the reimbursement 
system. 
Conclusion
 To answer question why, when, and how 
off-label use and prescribing of medicine should 
be included in unversal coverage reimbursement 
system, here are some thought to be concluded:
 Why off-label use and prescribing 
of medicine should be included in unversal 
coverage reimbursement system? Off label use 
and prescribing of medicine is not uncommon and 
can be seen in the standard of care. The practices of 
it mostly done in vurnerable population (population 
excluded from clinical trials), a licensed drug for 
certain indication is not available (e.g. oprhan or 
rare diseases), there is limited or even a broad 
evidence of the safety and efficacy/effectiveness 
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of certain licensed medicine to be used off-label 
but the manufacturer is reluctant to licensed it. It is 
not illegal to give treatment or care using off-label 
medicine. Lawsuit regarding off-label medicine 
are performed due to failure to provide adequate 
informed consent for using and prescribing off-label 
medicine to patient, and medical negligence (failure 
to provide adequate information). Leaving patient 
without a proper treatment is regarded unethical 
especially when physicians aware that there is a 
cure although not yet registered, and limiting the use 
of licensed medicine “only” in the reimbursement 
systems is somehow considered discouraging the 
efforts to provide equity for essential treatment and 
access to medicine.
When is off-label use and prescribing of medicine 
is included in the universal coverage system? 
There are six proposed condition, i.e. (1). Presence 
of a severe, life-impairing or life-threatening 
condition; (2). Absence of authorized treatment or 
repeated treatment failure; (3)  Absence of alternative 
treatments authorized for the condition; (4) The off-
label use is supported by strong evidence in scientific 
literature; (5) The patient has been educated and has 
given his or her informed consent; (6) Presence of 
established reporting routes for adverse events and 
linked to off-label use.6
How is off-label use and prescribing of medicine 
is included in the universal coverage system? 
The reimbursement system shall provide the easiness 
to access off-label use and prescribing of medicine 
especially it is supported by strong evidence that 
the safety, efficacy/effectiveness, and/or efficiency 
exists. Including an off-label medicine in a National 
List of Essential Medicine or National Formulary 
is a start to put it on the reimbursement systems. 
A system of registry and monitoring for serious 
adverse effects should be developed and established, 
to ensure the safety of off-label use and prescribing.
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